Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 2

Lubiprostone: a novel treatment for chronic constipation

Authors Brian E Lacy, L Campbell Levy

Published 6 June 2008 Volume 2008:3(2) Pages 357—364

DOI https://dx.doi.org/10.2147/CIA.S2938

Brian E Lacy, L Campbell Levy

Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon NH, USA

Abstract: Chronic constipation is highly prevalent, reduces patients’ quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the use of prescription medications. Three prescription medications are currently Food and Drug Administration (FDA) approved and available for the treatment of chronic constipation in adults. This review will focus on lubiprostone, the newest medication available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite analogue of prostaglandin E1. It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit, and improve symptoms of constipation. This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication.

Keywords: chloride, chloride channels, constipation, functional bowel disorders, gastrointestinal motility, intestinal secretion, irritable bowel syndrome, lubiprostone

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Readers of this article also read:

Decreased expression of APAF-1 and increased expression of cathepsin B in invasive pituitary adenoma

Tanase C, Albulescu R, Codrici E, Calenic B, Popescu ID, Mihai S, Necula L, Cruceru ML, Hinescu ME

OncoTargets and Therapy 2015, 8:81-90

Published Date: 22 December 2014

Role of PTPN22 and VDR gene polymorphisms in susceptibility to rheumatoid arthritis: a study from central India

Shukla S, Tripathi AK, Tripathi JK, Indurkar M, Chauhan UK

Advances in Genomics and Genetics 2014, 4:79-85

Published Date: 19 June 2014

Biological activity of lactoferrin-functionalized biomimetic hydroxyapatite nanocrystals

Nocerino N, Fulgione A, Iannaccone M, Tomasetta L, Ianniello F, Martora F, Lelli M, Roveri N, Capuano F, Capparelli R

International Journal of Nanomedicine 2014, 9:1175-1184

Published Date: 5 March 2014

Valuing the person’s story: Use of life story books in a continuing care setting

Teresa Wills, Mary Rose Day

Clinical Interventions in Aging 2008, 3:547-552

Published Date: 12 September 2008

Editorial ||Free paper||

Thomas J Webster

International Journal of Nanomedicine 2008, 3:0-0

Published Date: 6 June 2008

Treatment of adults with attention-deficit/hyperactivity disorder

Dusan Kolar, Amanda Keller, Maria Golfinopoulos, Lucy Cumyn, Cassidy Syer, Lily Hechtman

Neuropsychiatric Disease and Treatment 2008, 4:107-121

Published Date: 8 February 2008

Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder

Feng Liu, Haruka Minami, Raul R Silva

Neuropsychiatric Disease and Treatment 2006, 2:467-473

Published Date: 15 December 2006

Rizatriptan in the treatment of migraine

Miguel JA Láinez

Neuropsychiatric Disease and Treatment 2006, 2:247-259

Published Date: 15 September 2006

Bupropion SR in adults with ADHD: a short-term, placebo-controlled trial

Frederick W Reimherr, Dawson W Hedges, Robert E Strong, Barrie K Marchant, Erika D Williams

Neuropsychiatric Disease and Treatment 2005, 1:245-251

Published Date: 15 October 2005